Dataset Information

Impact analysis of heart failure across European countries: an ESC-HFA position paper.

ABSTRACT: Heart failure (HF) is a long-term clinical syndrome, with increasing prevalence and considerable healthcare costs that are further expected to increase dramatically. Despite significant advances in therapy and prevention, mortality and morbidity remain high and quality of life poor. Epidemiological data, that is, prevalence, incidence, mortality, and morbidity, show geographical variations across the European countries, depending on differences in aetiology, clinical characteristics, and treatment. However, data on the prevalence of the disease are scarce, as are those on quality of life. For these reasons, the ESC-HFA has developed a position paper to comprehensively assess our understanding of the burden of HF in Europe, in order to guide future policies for this syndrome. This manuscript will discuss the available epidemiological data on HF prevalence, outcomes, and human costs-in terms of quality of life-in European countries.

SUBMITTER: Rosano GMC

PROVIDER: S-EPMC9715845 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Impact analysis of heart failure across European countries: an ESC-HFA position paper.

Rosano Giuseppe M C GMC Seferovic Petar P Savarese Gianluigi G Spoletini Ilaria I Lopatin Yuri Y Gustafsson Fin F Bayes-Genis Antoni A Jaarsma Tiny T Abdelhamid Magdy M Miqueo Arantxa Gonzalez AG Piepoli Massimo M Tocchetti Carlo G CG Ristić Arsen D AD Jankowska Ewa E Moura Brenda B Hill Loreena L Filippatos Gerasimos G Metra Marco M Milicic Davor D Thum Thomas T Chioncel Ovidiu O Ben Gal Tuvia T Lund Lars H LH Farmakis Dimitrios D Mullens Wilfried W Adamopoulos Stamatis S Bohm Michael M Norhammar Anna A Bollmann Andreas A Banerjee Amitava A Maggioni Aldo P AP Voors Adriaan A Solal Alain Cohen AC Coats Andrew J S AJS

ESC heart failure 20220722 5

Heart failure (HF) is a long-term clinical syndrome, with increasing prevalence and considerable healthcare costs that are further expected to increase dramatically. Despite significant advances in therapy and prevention, mortality and morbidity remain high and quality of life poor. Epidemiological data, that is, prevalence, incidence, mortality, and morbidity, show geographical variations across the European countries, depending on differences in aetiology, clinical characteristics, and treatme ...[more]

PMID: 35869679

Similar Datasets

Project description:Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain significant in Europe and are increasing worldwide. Patients with IHD or HF might benefit from novel therapeutic strategies, such as cell-based therapies. We recently discussed the therapeutic potential of cell-based therapies and provided recommendations on how to improve the therapeutic translation of these novel strategies for effective cardiac regeneration and repair. Despite major advances in optimizing these strategies with respect to cell source and delivery method, the clinical outcome of cell-based therapy remains unsatisfactory. Major obstacles are the low engraftment and survival rate of transplanted cells in the harmful microenvironment of the host tissue, and the paucity or even lack of endogenous cells with repair capacity. Therefore, new ways of delivering cells and their derivatives are required in order to empower cell-based cardiac repair and regeneration in patients with IHD or HF. Strategies using tissue engineering (TE) combine cells with matrix materials to enhance cell retention or cell delivery in the transplanted area, and have recently received much attention for this purpose. Here, we summarize knowledge on novel approaches emerging from the TE scenario. In particular, we will discuss how combinations of cell/bio-materials (e.g. hydrogels, cell sheets, prefabricated matrices, microspheres, and injectable matrices) combinations might enhance cell retention or cell delivery in the transplantation areas, thereby increase the success rate of cell therapies for IHD and HF. We will not focus on the use of classical engineering approaches, employing fully synthetic materials, because of their unsatisfactory material properties which render them not clinically applicable. The overall aim of this Position Paper from the ESC Working Group Cellular Biology of the Heart is to provide recommendations on how to proceed in research with these novel TE strategies combined with cell-based therapies to boost cardiac repair in the clinical settings of IHD and HF.

Dataset Information

Impact analysis of heart failure across European countries: an ESC-HFA position paper.

Publications

Impact analysis of heart failure across European countries: an ESC-HFA position paper.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets